In last trading session, Ikena Oncology Inc (NASDAQ:IKNA) saw 1.47 million shares changing hands with its beta currently measuring 0.35. Company’s recent per share price level of $1.50 trading at -$0.05 or -3.54% at ring of the bell on the day assigns it a market valuation of $72.39M. That closing price of IKNA’s stock is at a discount of -409.33% from its 52-week high price of $7.64 and is indicating a premium of 32.0% from its 52-week low price of $1.02. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.42 million shares which gives us an average trading volume of 372.98K if we extend that period to 3-months.
Ikena Oncology Inc (NASDAQ:IKNA) trade information
Upright in the red during last session for losing -3.54%, in the last five days IKNA remained trading in the green while hitting it’s week-highest on Friday, 03/15/24 when the stock touched $1.50 price level, adding 6.54% to its value on the day. Ikena Oncology Inc’s shares saw a change of -23.86% in year-to-date performance and have moved 2.74% in past 5-day. Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of 12.78% in past 30-days. Number of shares sold short was 0.97 million shares which calculate 1.61 days to cover the short interests.
Ikena Oncology Inc (IKNA) estimates and forecasts
Statistics highlight that Ikena Oncology Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -65.20% of value to its shares in past 6 months, showing an annual growth rate of 7.98% while that of industry is 12.10. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -5.10% in the current quarter and calculating 11.40% increase in the next quarter. This year revenue growth is estimated to fall -23.60% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.75 million for the same. And 4 analysts are in estimates of company making revenue of $1.75 million in the next quarter that will end on Jun 2024. Company posted $5.31 million and $3.08 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -67.10% while estimating it to be -43.20% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -7.46% during past 5 years.
IKNA Dividends
Ikena Oncology Inc is more likely to be releasing its next quarterly report in April and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Ikena Oncology Inc (NASDAQ:IKNA)’s Major holders
Insiders are in possession of 7.00% of company’s total shares while institution are holding 100.56 percent of that, with stock having share float percentage of 108.12%. Investors also watch the number of corporate investors in a company very closely, which is 100.56% institutions for Ikena Oncology Inc that are currently holding shares of the company. Orbimed Advisors LLC. is the top institutional holder at IKNA for having 9.4 million shares of worth $61.67 million. And as of Jun 29, 2023, it was holding 25.09% of the company’s outstanding shares.
The second largest institutional holder is FMR, LLC, which was holding about 5.07 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 13.53% of outstanding shares, having a total worth of $33.26 million.
On the other hand, Fidelity Advisor Biotechnology Fund and Fidelity Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Jul 30, 2023, the former fund manager was holding 1.54 million shares of worth $7.94 million or 4.11% of the total outstanding shares. The later fund manager was in possession of 1.07 million shares on Jul 30, 2023, making its stake of worth around $5.51 million in the company or a holder of 2.86% of company’s stock.
